Combining the power of science and empathy to unravel the inner workings of cancer and develop innovative therapies that restore hope to those with cancer and their loved ones.

Areas of focus

A diagnosis of breast cancer, the most common cancer worldwide, is life changing for patients, their families and loved ones. Listening and learning from their real-life experiences is key. We are working on improving access to and participation by patient populations who are often underrepresented in clinical trials, identifying new pathways or mutations that may play a role in disease progression and developing therapies with a goal of extending and improving the lives of those with breast cancer.

Learn more

More men are receiving a diagnosis of prostate cancer than ever before. At Novartis, we are harnessing the innovation of our world-class scientists, strategic partnerships, and one of the industry’s most competitive pipelines to make the promise of next-generation medicines a reality to address unmet needs in care.

Learn more

Globally, more than 2 million people are diagnosed with lung cancer each year, and each one has a unique experience that must be considered. Through cutting-edge science and technology, we are finding new ways to explore therapies with a goal of improving outcomes for each individual with lung cancer.

Learn more

Innovative therapies introduced over the past two decades have revolutionized treatment for people with CML, a serious and life-threatening blood disorder. Even with the innovations seen in this space, some patients still experience resistance and/or intolerance to currently available therapies, which means that CML can remain a devastating diagnosis. More work needs to be done to turn scientific breakthroughs into medicines so that more people can benefit from life-changing medicines.

Learn more

Even though neuroendocrine tumors (NETs) are considered slow-growing malignancies, people with this type of cancer can experience rapid progression and poor prognosis. In many cases, diagnosis is delayed until patients have advanced disease, often making the impact of the disease more devastating. Even though NETs are considered rare, the number of people affected has grown over 500% in the last three decades, reinforcing the need for innovative treatment options for those who are newly diagnosed with inoperable or advanced cancer.

Learn more

Radioligand therapy (RLT)

Novartis is reimagining cancer care with radioligand therapy (RLT) for patients with advanced cancers. RLT is a form of precision nuclear medicine that may recognize and treat disease.

Radioligand Therapy

Events and scientific meetings


AACRAmerican Association for Cancer Research
ASCOAmerican Society of Clinical Oncology
ASCO GIAmerican Society of Clinical Oncology, Gastrointestinal Cancers…
ASCO GUAmerican Society of Clinical Oncology, Genitourinary Cancers…
ASHAmerican Society of Hematology
AUAAmerican Urological Association
EANMEuropean Association of Nuclear Medicine
EAUEuropean Association of Urology
EHAEuropean Hematology Association
EMBTFormerly the European Society for Blood and Marrow Transplantation
ENETSEuropean Neuroendocrine Tumor Society
ASMOIASLCEuropean Society For Medical Oncology International Association of the Study of Lung Cancer…
SABCSSan Antonio Breast Cancer Symposium